Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis.
Schwarz C, Eschenhagen P, Schmidt H, Hohnstein T, Iwert C, Grehn C, Roehmel J, Steinke E, Stahl M, Lozza L, Tikhonova E, Rosati E, Stervbo U, Babel N, Mainz JG, Wisplinghoff H, Ebel F, Jia LJ, Blango MG, Hortschansky P, Brunke S, Hube B, Brakhage AA, Kniemeyer O, Scheffold A, Bacher P. Schwarz C, et al. J Clin Invest. 2023 Mar 1;133(5):e161593. doi: 10.1172/JCI161593. J Clin Invest. 2023. PMID: 36701198 Free PMC article.
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C. Mainz JG, et al. Among authors: schwarz c. Front Pharmacol. 2023 May 3;14:1207356. doi: 10.3389/fphar.2023.1207356. eCollection 2023. Front Pharmacol. 2023. PMID: 37205908 Free PMC article.
A prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled Tobramycin in patients with ventilator-associated pneumonia (iToVAP).
Angermair S, Deja M, Thronicke A, Grehn C, Akbari N, Uhrig A, Asgarpur G, Spies C, Treskatsch S, Schwarz C. Angermair S, et al. Among authors: schwarz c. Anaesth Crit Care Pain Med. 2023 Oct;42(5):101249. doi: 10.1016/j.accpm.2023.101249. Epub 2023 May 20. Anaesth Crit Care Pain Med. 2023. PMID: 37217019 Free article. Clinical Trial.
Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy.
Eschenhagen PN, Bacher P, Grehn C, Mainz JG, Scheffold A, Schwarz C. Eschenhagen PN, et al. Among authors: schwarz c. Front Pharmacol. 2023 Jun 20;14:1180826. doi: 10.3389/fphar.2023.1180826. eCollection 2023. Front Pharmacol. 2023. PMID: 37408761 Free PMC article.
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Mainz JG, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L, Sadrieh P, Nährlich L, Eickmeier O, Van Dullemen S, Eschenhagen P, Schwarz C, Lüth S, Zagoya C, Graepler-Mainka U. Mainz JG, et al. Among authors: schwarz c. Front Pharmacol. 2023 Oct 25;14:1167407. doi: 10.3389/fphar.2023.1167407. eCollection 2023. Front Pharmacol. 2023. PMID: 38026920 Free PMC article.
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Schwarz C, Bend J, Hebestreit H, Hogardt M, Hügel C, Illing S, Mainz JG, Rietschel E, Schmidt S, Schulte-Hubbert B, Sitter H, Wielpütz MO, Hammermann J, Baumann I, Brunsmann F, Dieninghoff D, Eber E, Ellemunter H, Eschenhagen P, Evers C, Gruber S, Koitschev A, Ley-Zaporozhan J, Düesberg U, Mentzel HJ, Nüßlein T, Ringshausen FC, Sedlacek L, Smaczny C, Sommerburg O, Sutharsan S, Vonberg RP, Weber AK, Zerlik J. Schwarz C, et al. Pneumologie. 2024 Jun;78(6):e2. doi: 10.1055/a-2278-6685. Epub 2024 Feb 29. Pneumologie. 2024. PMID: 38423036 German. No abstract available.
ECFS standards of care on CFTR-related disorders: Identification and care of the disorders.
Simmonds NJ, Southern KW, De Wachter E, De Boeck K, Bodewes F, Mainz JG, Middleton PG, Schwarz C, Vloeberghs V, Wilschanski M, Bourrat E, Chalmers JD, Ooi CY, Debray D, Downey DG, Eschenhagen P, Girodon E, Hickman G, Koitschev A, Nazareth D, Nick JA, Peckham D, VanDevanter D, Raynal C, Scheers I, Waller MD, Sermet-Gaudelus I, Castellani C; ECFS Diagnostic Network Working Group. Simmonds NJ, et al. Among authors: schwarz c. J Cyst Fibros. 2024 Jul;23(4):590-602. doi: 10.1016/j.jcf.2024.03.008. Epub 2024 Mar 19. J Cyst Fibros. 2024. PMID: 38508949 Free article.
Success of the German Cystic Fibrosis Registry.
Naehrlich L, Burkhart M; Registry Working Group of the German CF Registry. Naehrlich L, et al. Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70076. doi: 10.1002/pds.70076. Pharmacoepidemiol Drug Saf. 2025. PMID: 39775994 Free PMC article.
Clinical Relevance of Fungi in Cystic Fibrosis.
Schwarz C. Schwarz C. Semin Respir Crit Care Med. 2023 Apr;44(2):252-259. doi: 10.1055/s-0042-1759882. Epub 2023 Feb 6. Semin Respir Crit Care Med. 2023. PMID: 36746184
1,180 results